Acquired by Novo Holdings in Jan 2025
CTLT - Catalent, Inc.
NYSE
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Somerset,
United States
Type: Equity
CTLT price evolution
CTLT
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $289 | $162 | $229 | |
| Short term investments | ||||
| Net receivables | $1352 | $921 | $875 | $843 |
| Inventory | $583 | $574 | $742 | $775 |
| Total current assets | $2507 | $2597 | $2523 | $2570 |
| Long term investments | ||||
| Property, plant & equipment | $3671 | $3643 | $3735 | $3777 |
| Goodwill & intangible assets | $3174 | $3214 | $3262 | |
| Total noncurrent assets | $7156 | $7356 | $7418 | |
| Total investments | ||||
| Total assets | $9708 | $9753 | $9879 | $9988 |
| Current liabilities | ||||
| Accounts payable | $375 | $361 | $377 | $407 |
| Deferred revenue | ||||
| Short long term debt | $48 | $47 | $46 | |
| Total current liabilities | $998 | $1031 | $1007 | $1036 |
| Long term debt | $4886 | $4857 | $4933 | $4959 |
| Total noncurrent liabilities | $5118 | $5261 | $5265 | |
| Total debt | $4905 | $4980 | $5005 | |
| Total liabilities | $6166 | $6149 | $6268 | $6301 |
| Shareholders' equity | ||||
| Retained earnings | -$910 | -$781 | -$804 | -$703 |
| Other shareholder equity | -$350 | $3604 | -$356 | -$354 |
| Total shareholder equity | $3604 | $3611 | $3687 | |
| (in millions $) | 30 Jul 2024 | 30 Jul 2023 | 31 Dec 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $289 | $449 | $896 | |
| Short term investments | $89 | $71 | ||
| Net receivables | $921 | $977 | $1051 | $1012 |
| Inventory | $574 | $764 | $702 | $563 |
| Total current assets | $2597 | $2679 | $2916 | $2918 |
| Long term investments | ||||
| Property, plant & equipment | $3643 | $3699 | $3127 | $2524 |
| Goodwill & intangible assets | $3174 | $4066 | $3336 | |
| Total noncurrent assets | $7156 | $7591 | $6194 | |
| Total investments | $89 | $71 | ||
| Total assets | $9753 | $10782 | $10507 | $9112 |
| Current liabilities | ||||
| Accounts payable | $361 | $427 | $421 | $385 |
| Deferred revenue | ||||
| Short long term debt | $48 | $31 | $75 | |
| Total current liabilities | $1031 | $1507 | $1072 | $1196 |
| Long term debt | $4857 | $4313 | $4171 | $3166 |
| Total noncurrent liabilities | $5118 | $4640 | $3642 | |
| Total debt | $4905 | $4202 | $3241 | |
| Total liabilities | $6149 | $6147 | $5712 | $4838 |
| Shareholders' equity | ||||
| Retained earnings | -$781 | $262 | $538 | $25 |
| Other shareholder equity | $3604 | $4635 | -$394 | -$317 |
| Total shareholder equity | $3604 | $4795 | $3915 | |
| (in millions $) | 1 May 2025 | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1023 | $1301 | ||
| Cost of revenue | ||||
| Gross Profit | $181 | $384 | ||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $253 | $278 | ||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $12 | $15 | ||
| Interest expense | -$50 | -$65 | ||
| Net income | ||||
| Net income | -$129 | $23 | ||
| Income (for common shares) | ||||
| (in millions $) | 30 Jul 2024 | 30 Jul 2023 | 31 Dec 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $4381 | $4276 | $4828 | $3998 |
| Cost of revenue | $3188 | $2646 | ||
| Gross Profit | $953 | $1060 | $1640 | $1352 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $844 | $687 | ||
| Total operating expenses | $1015 | $987 | $885 | $706 |
| Operating income | $755 | $646 | ||
| Income from continuing operations | ||||
| EBIT | $728 | $825 | ||
| Income tax expense | $16 | -$83 | $86 | $130 |
| Interest expense | -$254 | -$184 | $123 | $110 |
| Net income | ||||
| Net income | -$1043 | -$232 | $519 | $585 |
| Income (for common shares) | $503 | $529 | ||
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $23 | -$101 | -$206 | |
| Operating activities | ||||
| Depreciation | $130 | $126 | $121 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $16 | $17 | $16 | |
| Total cash flows from operations | $214 | $12 | $112 | |
| Investing activities | ||||
| Capital expenditures | -$75 | -$74 | -$94 | |
| Investments | $1 | -$1 | ||
| Total cash flows from investing | -$34 | -$74 | -$74 | -$95 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $8 | |||
| Net borrowings | -$5 | -$4 | $13 | |
| Total cash flows from financing | -$10 | -$10 | -$14 | |
| Effect of exchange rate | $29 | -$3 | -$5 | $17 |
| Change in cash and equivalents | $46 | $127 | -$67 | $20 |
| (in millions $) | 31 Dec 2024 | 30 Jul 2023 | 31 Dec 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Net income | -$1043 | $519 | $585 | |
| Operating activities | ||||
| Depreciation | $489 | $378 | $289 | |
| Business acquisitions & disposals | -$1199 | $140 | ||
| Stock-based compensation | $68 | $54 | $51 | |
| Total cash flows from operations | $268 | $439 | $433 | |
| Investing activities | ||||
| Capital expenditures | -$326 | -$660 | -$686 | |
| Investments | -$1 | -$22 | -$103 | |
| Total cash flows from investing | -$327 | -$955 | -$1884 | -$649 |
| Financing activities | ||||
| Dividends paid | -$4 | -$22 | ||
| Sale and purchase of stock | $9 | $26 | $120 | |
| Net borrowings | $84 | $1022 | $99 | |
| Total cash flows from financing | $74 | $521 | $1031 | $142 |
| Effect of exchange rate | -$6 | $11 | -$33 | $17 |
| Change in cash and equivalents | $9 | -$169 | -$447 | -$57 |
News
Fundamentals
| Market cap | $11.49B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 181.00M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 1.71 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.51 |
| Quick ratio | 1.93 |